삼성서울병원

Ko En

Park, Se Hoon M.D

TITLE
Professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Treament Schedule 11 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
AM
PM
Treament Schedule 12 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical School

Konkuk University College of Medicine, Seoul, Korea

Specialty Training

Fellowship   Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea
Residency   Samsung Medical Center, Seoul, Korea
Internship   Samsung Medical Center, Seoul, Korea

Clinical & Research Interests

Chemotherapy and clinical trials in gastrointestinal and genitourinary cancers

Participation in Academic Societies
and Research

A member of the Korean Cancer Association and the Korean Association for Clinical Oncology
A member of the American Society of Clinical Oncology and the European Society for Medical Oncology

Selected Publications

  • LANCET ONCOL 2020 10.1016/S1470-2045(20)30541-6 Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) a randomised, open-label, multicentre, phase 3 trial Powles1, T; van der Heijden, MS; Castellano, D; Galsky, MD; Loriot, Y; Petrylak, DP; Ogawa, O; Park, SN; Lee, JL; De Giorgi, U; Bogemann, M; Bamias, A; Eigl, BJ; Gurney, H; Mukherjee, SD; Fradet, Y; Skoneczna, I; Tsiatas, M; Novikov, A; Suarez, C; Fay, AP; Duran, I; Necchi, A; Wildsmith, S; He, P; Angra, N; Gupta, AK; Levin, W; Bellmunt, J
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • INVESTIG CLIN UROL 2020 10.4111/icu.20200214 Docetaxel rechallenge in metastatic castration-resistant prostate cancer A retrospective, single-center study Byeon1, S; Kim, H; Kim, J; Kwon, M; Hur, JY; Jeon, HG; Jeon, SS; Lee, HM; Park, SH
    View PubMed
  • CANCER SCI 2020 10.1111/cas.14681 Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma Ye1, DW; Liu, JY; Zhou, AP; Zou, Q; Li, HZ; Fu, C; Hu, HL; Huang, J; Zhu, SX; Jin, J; Ma, LL; Guo, JM; Xiao, J; Park, SH; Zhang, DH; Qiu, XS; Bao, YY; Zhang, LL; Shen, W; Bi, F
    View PubMed
  • RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
    View PubMed